Background:
Nutra Pharma Corporation, a development stage biopharmaceutical company, specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Its subsidiary, ReceptoPharm, Inc., develops technologies for the production of drugs for HIV and multiple sclerosis. Nutra Pharma's other subsidiary, Designer Diagnostics, Inc., engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as tuberculosis and mycobacterium avium-intracellulare.
Recent News:
Nutra Pharma Announces ReceptoPharm Patent for a Method of Treating Multiple Sclerosis
April 11, 2007: Nutra Pharma Corp... has today announced that its drug discovery division, ReceptoPharm, has filed a patent for a method of treating autoimmune diseases, including Multiple Sclerosis (MS) and Rheumatoid Arthritis. http://biz.yahoo.com/bw/070411/20070411005303.html?.v=1
Nutra Pharma Completes First Royalty Payment to Nanologix for Test Kit Technology
March 27, 2007: Nutra Pharma Corp... has today announced that it has completed its first royalty payment to NanoLogix, Inc. or the licensing rights to the technology used in the Designer Diagnostics test kits. biz.yahoo.com/bw/070327/20070327005570.html
$0.1 (04/13/07)
